PennyStockPayCheck.com Rss

Featured Posts

Chase Bank Limits Cash Withdrawals, Bans International... Before you read this report, remember to sign up to http://pennystockpaycheck.com for 100% free stock alerts Chase Bank has moved to limit cash withdrawals while banning business customers from sending...

Read more

Richemont chairman Johann Rupert to take 'grey gap... Billionaire 62-year-old to take 12 months off from Cartier and Montblanc luxury goods groupRichemont's chairman and founder Johann Rupert is to take a year off from September, leaving management of the...

Read more

Cambodia: aftermath of fatal shoe factory collapse... Workers clear rubble following the collapse of a shoe factory in Kampong Speu, Cambodia, on Thursday

Read more

Spate of recent shock departures by 50-something CEOs While the rising financial rewards of running a modern multinational have been well publicised, executive recruiters say the pressures of the job have also been ratcheted upOn approaching his 60th birthday...

Read more

UK Uncut loses legal challenge over Goldman Sachs tax... While judge agreed the deal was 'not a glorious episode in the history of the Revenue', he ruled it was not unlawfulCampaign group UK Uncut Legal Action has lost its high court challenge over the legality...

Read more

Cramer’s ‘Mad Money’ Recap: A Portfolio From Your Morning Routine

Category : Business, Stocks

Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

NEW YORK (TheStreet) — Nobody ever said the stock market was easy, Jim Cramer told “Mad Money” viewers Monday, but that doesn’t mean it has to be. Cramer said the markets can be difficult, but only if you overthink them. …

Click to view a price quote on INTC.

Click to research the Electronics industry.

Read the original post: Cramer’s ‘Mad Money’ Recap: A Portfolio From Your Morning Routine

Post to Twitter

Vivus, Arena Obesity Drugs Will Be Approved, Investors Say

Category : Stocks

Updates with current stock prices.

BOSTON (TheStreet) –Both Vivus and Arena Pharmaceuticals are expected to receive final approval for their rival obesity drugs although confidence in the former is significantly higher, according investors who submitted entries to TheStreet’s latest FDA Drug Approval Contest.

Nearly 77% of investors predict FDA will approve Vivus’ Qnexa on or before July 17 — an overwhelming margin compared to the 19% of investors predicting rejection. Another 4% of investors believe FDA will delay the Qnexa decision for a second time. …

Click to view a price quote on ARNA.

Click to research the Drugs industry.

Read more here: Vivus, Arena Obesity Drugs Will Be Approved, Investors Say

Post to Twitter

Stocks Hit 52-Week Highs: Altria, Lumber Liquidators

Category : Business, Stocks

NEW YORK (TheStreet) — These stocks reached 52-week highs on Tuesday: Lumber Liquidators, Altria, Skechers and Arena Pharmaceuticals.

Lumber Liquidators

Shares of Lumber Liquidators hit a 52-week high on Tuesday of $30.81. The stock’s 52-week low of $13.43 was set on Sept. 6. …

Click to view a price quote on MO.

Click to research the Tobacco industry.

Excerpt from: Stocks Hit 52-Week Highs: Altria, Lumber Liquidators

Post to Twitter

7 Stocks Under $10 Soaring Higher

Category : Business

WINDERMERE, Fla. (Stockpickr) — At Stockpickr, we track daily portfolios of stocks that are the biggest percentage gainers and the biggest percentage losers.

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility. Stocks that are making big-percentage moves either up or down are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst upgrade.

>>5 Stocks Setting Up to Break Out …

Click to view a price quote on ARNA.

Click to research the Drugs industry.

The rest is here: 7 Stocks Under $10 Soaring Higher

Post to Twitter

Vivus Shares Soar; FDA Panel Recommends Qnexa Approval

Category : Stocks

NEW YORK (TheStreet) — Shares of VIVUS soared late Wednesday after the company confirmed a Food and Drug Administration advisory committee has recommended Qnexa, its proposed treatment for obesity in adults, receive marketing approval.

The stock was last quoted at $21.02, up 99.2%, on volume of 1.9 million, according to Nasdaq.com.

“We are pleased with the panel’s approval recommendation in support of the safety and efficacy of Qnexa,” said Peter Tam, the company’s president, in a statement. “We look forward to working with the FDA as they complete their evaluation. Obesity is a serious medical condition, and we are committed to making Qnexa available and providing physicians with a new medical treatment option in their battle with this public health epidemic.”

Click to view a price quote on VVUS.

Click to research the Drugs industry.

View original post here: Vivus Shares Soar; FDA Panel Recommends Qnexa Approval

Post to Twitter